Court Dismisses Exact Sciences’ ‘781 Patent Infringement Claim Against Geneoscopy
Geneoscopy Continues Path Toward Commercialization of ColoSense, Bringing New Innovations in Gastrointestinal Health to Patients in Need ST, LOUIS,…
Geneoscopy Expands Leadership Team to Support ColoSense™ Rollout and Advance Precision IBD Solution
ST, LOUIS, MO – MAY 15, 2024 – Geneoscopy, Inc., a life sciences company focused on developing diagnostic tests for the advancement of…
FDA Approves ColoSense™ - Geneoscopy's Noninvasive Multi-target Stool RNA (mt-sRNA) Colorectal Cancer Screening Test
In average-risk individuals, ColoSense demonstrated 93% sensitivity for detecting colorectal cancer (CRC) and 45% sensitivity for detecting advanced…
Geneoscopy to Present Research on Inflammatory Bowel Disease at Crohn’s & Colitis Foundation’s IBD Innovate 2024 Conference
Data shows noninvasive stool RNA technology may help providers assess therapeutic response and monitor disease activity for patients with…
Geneoscopy Forms Scientific Advisory Board to Support Advancement of Precision Immunology Diagnostics for Inflammatory Bowel Disease (IBD)
ST. LOUIS, MO – January 17, 2024 – Geneoscopy, Inc., a life sciences company focused on developing diagnostic tests for the advancement of…
Geneoscopy Files Inter Partes Review Petition Challenging Exact Sciences’ Patent
Extensive prior art renders Exact Sciences’ patent relating to stool collection and processing invalid ST. LOUIS, Mo. – (BUSINESS WIRE)…
Geneoscopy Signs Multi-Year Agreement with Labcorp to Distribute Noninvasive Multi-Target Stool RNA (mt-sRNA) Colorectal Cancer Screening Test
Collaboration expected to increase provider and patient access to potentially life-saving colorectal cancer screening that enables earlier disease…
Don Hardison Appointed Chairman of the Board at Geneoscopy
ST. LOUIS. MO – November 9, 2023 – Geneoscopy, a life sciences company focused on developing diagnostic tests for gastrointestinal health, has…